Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. more
Time Frame | MDWD | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.37% | -2.82% | 0.15% |
1-Month Return | 1.12% | -4.22% | 1.78% |
3-Month Return | -2.9% | -9.52% | 8.7% |
6-Month Return | 6.34% | -3.45% | 12.24% |
1-Year Return | 67.48% | 5.62% | 30.9% |
3-Year Return | 5.75% | 3.8% | 30.19% |
5-Year Return | -18.57% | 39.68% | 91.72% |
10-Year Return | -63.76% | 105.02% | 203.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 31.79M | 21.76M | 23.76M | 26.50M | 18.69M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.46,"profit":true},{"date":"2021-12-31","value":74.75,"profit":true},{"date":"2022-12-31","value":83.35,"profit":true},{"date":"2023-12-31","value":58.78,"profit":true}] |
Cost of Revenue | 11.85M | 14.22M | 14.99M | 13.33M | 15.11M | [{"date":"2019-12-31","value":78.43,"profit":true},{"date":"2020-12-31","value":94.11,"profit":true},{"date":"2021-12-31","value":99.23,"profit":true},{"date":"2022-12-31","value":88.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 19.94M | 7.54M | 8.77M | 13.16M | 3.58M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":37.84,"profit":true},{"date":"2021-12-31","value":43.99,"profit":true},{"date":"2022-12-31","value":66.02,"profit":true},{"date":"2023-12-31","value":17.94,"profit":true}] |
Gross Margin | 62.73% | 34.67% | 36.91% | 49.69% | 19.15% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":55.27,"profit":true},{"date":"2021-12-31","value":58.84,"profit":true},{"date":"2022-12-31","value":79.21,"profit":true},{"date":"2023-12-31","value":30.53,"profit":true}] |
Operating Expenses | 15.45M | 16.39M | 19.99M | 21.51M | 18.87M | [{"date":"2019-12-31","value":71.81,"profit":true},{"date":"2020-12-31","value":76.17,"profit":true},{"date":"2021-12-31","value":92.94,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.72,"profit":true}] |
Operating Income | 4.49M | (8.84M) | (11.22M) | (8.35M) | (15.29M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-196.75,"profit":false},{"date":"2021-12-31","value":-249.74,"profit":false},{"date":"2022-12-31","value":-185.73,"profit":false},{"date":"2023-12-31","value":-340.31,"profit":false}] |
Total Non-Operating Income/Expense | (4.98M) | (985.00K) | (3.38M) | (13.43M) | 14.65M | [{"date":"2019-12-31","value":-33.97,"profit":false},{"date":"2020-12-31","value":-6.72,"profit":false},{"date":"2021-12-31","value":-23.11,"profit":false},{"date":"2022-12-31","value":-91.7,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 2.07M | (9.28M) | (13.52M) | (19.52M) | (6.53M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-448.98,"profit":false},{"date":"2021-12-31","value":-654.6,"profit":false},{"date":"2022-12-31","value":-944.87,"profit":false},{"date":"2023-12-31","value":-316.12,"profit":false}] |
Income Taxes | (1.65M) | 325.00K | 27.00K | 78.00K | 185.00K | [{"date":"2019-12-31","value":-508.31,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":8.31,"profit":true},{"date":"2022-12-31","value":24,"profit":true},{"date":"2023-12-31","value":56.92,"profit":true}] |
Income After Taxes | 3.72M | (9.60M) | (13.55M) | (19.60M) | (6.72M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-258.23,"profit":false},{"date":"2021-12-31","value":-364.47,"profit":false},{"date":"2022-12-31","value":-527.14,"profit":false},{"date":"2023-12-31","value":-180.63,"profit":false}] |
Income From Continuous Operations | 2.07M | (9.28M) | (13.55M) | (19.60M) | (12.43M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-448.98,"profit":false},{"date":"2021-12-31","value":-655.91,"profit":false},{"date":"2022-12-31","value":-948.64,"profit":false},{"date":"2023-12-31","value":-601.65,"profit":false}] |
Income From Discontinued Operations | 2.89M | 80.00K | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":2.77,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 3.72M | (9.60M) | (13.55M) | (19.60M) | (6.72M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-258.23,"profit":false},{"date":"2021-12-31","value":-364.47,"profit":false},{"date":"2022-12-31","value":-527.14,"profit":false},{"date":"2023-12-31","value":-180.63,"profit":false}] |
EPS (Diluted) | 1.26 | (2.31) | (3.43) | (3.77) | (0.77) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-183.33,"profit":false},{"date":"2021-12-31","value":-272.22,"profit":false},{"date":"2022-12-31","value":-299.21,"profit":false},{"date":"2023-12-31","value":-61.11,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MDWD | |
---|---|
Cash Ratio | 1.78 |
Current Ratio | 2.11 |
Quick Ratio | 1.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MDWD | |
---|---|
ROA (LTM) | -15.77% |
ROE (LTM) | -75.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MDWD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.54 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.46 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MDWD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 9.19 |
P/B | 5.41 |
Price/FCF | NM |
EV/R | 7.40 |
EV/Ebitda | NM |
PEG | NM |
Mediwound Ltd (MDWD) share price today is $17.1
Yes, Indians can buy shares of Mediwound Ltd (MDWD) on Vested. To buy Mediwound Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MDWD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mediwound Ltd (MDWD) via the Vested app. You can start investing in Mediwound Ltd (MDWD) with a minimum investment of $1.
You can invest in shares of Mediwound Ltd (MDWD) via Vested in three simple steps:
The 52-week high price of Mediwound Ltd (MDWD) is $24. The 52-week low price of Mediwound Ltd (MDWD) is $10.06.
The price-to-earnings (P/E) ratio of Mediwound Ltd (MDWD) is
The price-to-book (P/B) ratio of Mediwound Ltd (MDWD) is 5.41
The dividend yield of Mediwound Ltd (MDWD) is 0.00%
The market capitalization of Mediwound Ltd (MDWD) is $184.83M
The stock symbol (or ticker) of Mediwound Ltd is MDWD